中國(guó)藥科大學(xué)生命科學(xué)與技術(shù)學(xué)院研究生導(dǎo)師介紹：徐寒梅

• 2025考研復(fù)試標(biāo)準(zhǔn)班
• 26考研全科上岸規(guī)劃營(yíng)「擇校▪規(guī)劃▪備考」
• 中國(guó)藥科大學(xué)2026考研專業(yè)課復(fù)習(xí)資料「真題▪筆記▪講義▪題庫(kù)」

徐寒梅，女，中國(guó)藥科大學(xué)生命科學(xué)與技術(shù)學(xué)院教授，博士生導(dǎo)師，海洋藥學(xué)教研室主任。自2002年于南京大學(xué)國(guó)家醫(yī)藥生物技術(shù)重點(diǎn)實(shí)驗(yàn)室進(jìn)行博士后研究期間，開始抗腫瘤蛋白質(zhì)及多肽的研究。2004年底到中國(guó)藥科大學(xué)工作，繼續(xù)從事抗腫瘤多肽的研究，設(shè)計(jì)合成了抗腫瘤多肽安替安吉肽,AP25，EDSM等具有自主知識(shí)產(chǎn)權(quán)的多肽，其中安替安吉肽于2013年9月獲得一類新藥臨床批件。近五年在國(guó)內(nèi)外發(fā)表學(xué)術(shù)文章50余篇，SCI20余篇；主編及參編論著各一部，主編教材《海洋制藥學(xué)》一部；申請(qǐng)發(fā)明專利共25項(xiàng)(其中國(guó)際專利5項(xiàng))。近五年以來，先后主持了：國(guó)家自然科學(xué)基金，國(guó)家“863”高科技發(fā)展計(jì)劃，國(guó)家“十一五”、“十二五”“重大新藥創(chuàng)制”科技重大專項(xiàng)，江蘇省校企合作前瞻性研究等項(xiàng)目，近五年帶領(lǐng)課題組（包括南京大學(xué)、武漢大學(xué)、廣州藥學(xué)院、醫(yī)藥企業(yè)）獲得國(guó)家資助3800余萬(wàn)元。因與企業(yè)合作抗腫瘤多肽研究的表現(xiàn)獲得內(nèi)蒙古自治區(qū)“杰出創(chuàng)新引進(jìn)人才”獎(jiǎng)，“草原英才”；近五年先后獲得江蘇省“青藍(lán)工程”優(yōu)秀骨干教師，中青年學(xué)術(shù)帶頭人，南京市領(lǐng)軍人才等獎(jiǎng)勵(lì)和稱號(hào)；因?yàn)楫a(chǎn)學(xué)研合作的表現(xiàn)被內(nèi)蒙古自治區(qū)政府聘為科技特派員;被教育部“藍(lán)火工程”聘為泰州市科技特派員。

聯(lián)系方式：1037714870@qq.com

辦公電話：86-025-86185437

近五年以第一作者或通訊作者發(fā)表的SCI論文文章

1. Shen Hong, Han Haibing, Hu Jialiang, Zhang Xiaojuan, Wang Jingjing, Wang Wenjing, Nie Caihui, Xu Hanmei*. PEGylated HM-3 presents anti-rheumatic bioactivity by inhibiting angiogenesis and inflammation. Journal of Materials Chemistry B, 2014, 2:800-813.
2. Jialiang Hu, Ming Yan, ChunyanPu, Jingjing Wang, Philippe E. Van den steen, GhislainOpdenakker, HanmeiXu*. Chemically synthesized matrix metalloproteinase- and angiogenesis-inhibiting peptides as anticancer agents. Anti-cancer Reagents ME. 2014 Mar;14(3):483-94.
3. Dongqing Yuan , Hong Shen , Songtao Yuan , Xiaoyi Liu, Xin Xia, Ping Xie , Weiguang Li , Jialiang Hu , Qinghuai Liu , Hanmei Xu*. Pharmacokinetics of HM-3 after intravitreal administration in mice. Current Eye Research. 2014, Feb 21,online.
4. Li Yongbing, Xu Hanmei*, Hu Jialiang, Zhang Fengguo, Liu Zhendong, Zhang Chi, Yang Yongjing, Pu Chunyan, Quantitative Analysis and Pharmacokinetics Study of Integrin Antagonist AP25 in Rat Plasma, Protein Pept Lett. 2012 Sep 4. [Epub ahead of print]
5. Chunyan Pu，Hanmei Xu*, Jialiang Hu, Zheng Heng, Xiaofeng Huang, Zhang Chi; Yongjing Yang, Yongbing Li, RGD position has effect on anti-angiogenic activity of RGD modified endostation derived synthetic polypeptides. Anti-cancer drugs. 2012, 12: 788-802
6. Li Pan1, Jialiang Hu1, Wenjing Wang1, Xiaojuan Zhang1, Jin Wei1, Zhendong Liu1, Yihua Zhang2* and Hanmei Xu1*. Molecular Mechanisms of (R,R) ZX-5 on NO Synthesis and Its Anti-Angiogenic Effect. International Journal of Molecular Sciences. 2012, 13, 2717-2726.
7. Liu Zhendong, Li Weiguang, Xu Hanmei*, Huang Xiaofeng, Pan Li, Ren Yinling, Yang Yongjing, Li Yongbing, Pu Chunyan, Zhang Chi. In vivo pharmacokinetics, immunogenicity and mechanism of PEGylated anti-tumor polypeptide. Current Pharmaceutical Design. 2012,18(12):1655-1662.
8.Guoqiu Wu, Xuepeng Deng，Pengpeng Wu, Zilong Shen, Hanmei Xu*, Subacute toxicity of antimicrobial peptide S-thanatin in ICR mice. Peptides 2012, 36 ( 1 ): 109-13.
9. Hanmei Xu*, Li Pan, Yinling Ren , et al.An RGD-Modified Angiogenesis Inhibitor HM-3 Dose: Dual Function during Cancer Treatment. Bioconjugate Chem., 2011, 22 (7): 1386–1393.
10. Zhendong Liu, Yinling Ren, Li Pan and Han-Mei Xu*, In Vivo Anti-Tumor Activity of Polypeptide HM-3 Modified by Different Polyethylene Glycols (PEG). Int. J. Mol. Sci. 2011, 12(4), 2650-2663.
11. Guoqiu Wu,Xuepeng Deng , Hanmei Xu*, et al. Application of immobilized thrombin for production of S-thanatin expressed in Escherichia coli. Appl Microbiol Biotechnol. 2011, 92(1):85-93.
12. Han-Mei Xu, Jin Wei, Zilong Shen1*, et al. The Mechanism of (R, R) ZX-5 Promoting Choroidal Blood Flow and Increasing NO Release, Int. J. Mol. Sci. 2010, 11(9), 3323-3333.
13. Ning-Hua Tan, Yu-Mei Zhang, Han-Mei Xu*, et al. A New Abietane Diterpene from Glyptostrobus pensilis, Fitoterapia,2010,81(8):1202-4.
14.Kang Zhou, Beili Zhu, Han-Mei Xu*, et al.Studies of polyethylene glycol modification of HM-3 polypeptides，Conference paper of 2010 Nanjing International Symposium on Pharmacogenomics and the Regulation of Drug Metabolism Enzymes and Genes, Journal of Nanjing University, 2010, Vol.46, 127-132
15. Beili Zhu, Han-Mei Xu*, Liming zhao, et al. Site-specific modification of antiangiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDa , Journal of Biochemistry, 2010, 148(3): 341-347
16. Runting Yin, Tao Xi and Han-Mei Xu*, et al. Effect of RGD-4C Position is More Important Than Disulfide Bonds on Antiangiogenic Activity of RGD-4C Modified Endostatin Derived Synthetic Polypeptide, bioconjugate chemistry, 2010, 6(1): 1142-1147
17. Zhou K, Zheng XQ, Xu HM* , et al. Studies of Poly(ethylene glycol) Modification of HM-3 Polypeptides, bioconjugate chemistry, 2010, 20(5): 932-936.
18. Han-Mei Xu*, Runting Yin, Xianghua Chen, et al. An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo，bioconjugate chemistry, 2008, 19(10): 1980-1986.
19. Siraj Sami, Han-Mei Xu*, Zilong Shen , et al. Valproic Acid Inhibits the Growth of Cervical Cancer both In vitro and In vivo, ， 144(3): 357-362.Journal of Biochemistry,2008